No Data
No Data
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug
Express News | Ascendis Pharma Presents 3-Year Data At ASBMR 2024 Showing Long-Term Treatment With TransCon PTH Normalizes Bone Remodeling In Adults With Hypoparathyroidism
Looking Into Ascendis Pharma's Recent Short Interest
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Ascendis Pharma A/S | 6-K: Report of foreign private issuer (related to financial reporting)
No Data
No Data